Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Jardiance (empagliflozin) and Metformin are both medications used to manage Type 2 diabetes, but they work in different ways and belong to different drug classes. Jardiance is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by causing your body to excrete excess sugar through urine. It also has benefits for heart failure and chronic kidney disease. Metformin, a biguanide, lowers the amount of sugar your body makes and absorbs, and helps your body use insulin more effectively. Jardiance is taken once daily and is currently only available as a brand-name medication, with generics expected after 2025. Metformin, on the other hand, is available in both short-acting and long-acting generic forms and is typically taken once or twice daily. Common side effects of Jardiance include urinary tract infections and yeast infections, while Metformin often causes stomach issues like diarrhea and nausea. Additionally, Jardiance can lead to dehydration and ketoacidosis, whereas Metformin carries a risk of lactic acidosis and low vitamin B12 levels.
Immediate-release metformin is an oral diabetes medication. It's approved for people 10 years of age and older with Type 2 diabetes. The medication belongs to the drug class called biguanides. It works best to lower blood sugar levels with a diabetes-friendly diet and exercise plan. Immediate-release metformin comes as a tablet and an oral solution. You take this medication by mouth usually two to three times a day. It's recommended to take each dosage with food to help lessen side effects like diarrhea and nausea.
Indications of Jardiance vs. Metformin
Indications for
•Type 2 diabetes (in addition to diet and exercise) in people age 10 years and older
•Lowering the risk of death due to heart problems in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in adults with heart failure
•Lowering the risk of worsening kidney problems, hospitalization, and death due to heart problems in adults with chronic kidney disease (CKD)